UY27966A1 - Inhibidores de factor xa y otras serinaproteasas implicadas en la cascada de la coagulación - Google Patents

Inhibidores de factor xa y otras serinaproteasas implicadas en la cascada de la coagulación

Info

Publication number
UY27966A1
UY27966A1 UY27966A UY27966A UY27966A1 UY 27966 A1 UY27966 A1 UY 27966A1 UY 27966 A UY27966 A UY 27966A UY 27966 A UY27966 A UY 27966A UY 27966 A1 UY27966 A1 UY 27966A1
Authority
UY
Uruguay
Prior art keywords
serinaproteases
involved
compounds
factor inhibitors
pharmaceutically acceptable
Prior art date
Application number
UY27966A
Other languages
English (en)
Inventor
Gary Louis Bolton
Kevin James Filipski
Jeffrey Thomas Kohrt
Frances Thu-La
Daniele Marie Leonard
Original Assignee
Warner Lambert Co
Warner Lambert Comany Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Warner Lambert Comany Llc filed Critical Warner Lambert Co
Publication of UY27966A1 publication Critical patent/UY27966A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Esta invención describe derivados de aminoácido que presentan efectos inhibitorios del factor Xa de serinaproteasa. La invención describe también sales farmacéuticamente aceptables de los compuestos, composiciones farmacéuticamente aceptables que comprenden los compuestos o sus sales, procedimientos para la preparación de los compuestos, y procedimientos para utilizarlos como agentes terapéuticos para tratar o prevenir estados patológicos en mamíferos caracterizados por una trombosis anormal.
UY27966A 2002-09-11 2003-09-09 Inhibidores de factor xa y otras serinaproteasas implicadas en la cascada de la coagulación UY27966A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40989102P 2002-09-11 2002-09-11

Publications (1)

Publication Number Publication Date
UY27966A1 true UY27966A1 (es) 2004-04-30

Family

ID=31994024

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27966A UY27966A1 (es) 2002-09-11 2003-09-09 Inhibidores de factor xa y otras serinaproteasas implicadas en la cascada de la coagulación

Country Status (14)

Country Link
US (1) US20040167131A1 (es)
EP (1) EP1539686A1 (es)
JP (1) JP2005538175A (es)
AR (1) AR041219A1 (es)
AU (1) AU2003260821A1 (es)
BR (1) BR0314219A (es)
CA (1) CA2497003A1 (es)
GT (1) GT200300192A (es)
MX (1) MXPA05002703A (es)
PA (1) PA8582001A1 (es)
PE (1) PE20041077A1 (es)
TW (1) TW200409622A (es)
UY (1) UY27966A1 (es)
WO (1) WO2004024679A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
WO2006063113A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
WO2015065876A1 (en) * 2013-10-29 2015-05-07 Thomas Jefferson University Methods of prevention or treatment for pathologic thrombosis or inflammation
CN113233996B (zh) * 2021-05-20 2022-05-20 河南大学 新型trpv1拮抗/faah抑制双靶点药物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
NZ333038A (en) * 1996-08-22 2000-10-27 Warner Lambert Co Non-peptide bombesin receptor antagonists
DE10036121A1 (de) * 2000-07-25 2002-02-07 Merck Patent Gmbh N-Substituierte-1-amino-1,1-dialkyl-carbonsäurederivate
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate

Also Published As

Publication number Publication date
PA8582001A1 (es) 2004-03-26
TW200409622A (en) 2004-06-16
JP2005538175A (ja) 2005-12-15
PE20041077A1 (es) 2005-02-05
WO2004024679A1 (en) 2004-03-25
EP1539686A1 (en) 2005-06-15
MXPA05002703A (es) 2005-05-05
BR0314219A (pt) 2005-07-19
GT200300192A (es) 2004-05-12
AU2003260821A1 (en) 2004-04-30
US20040167131A1 (en) 2004-08-26
CA2497003A1 (en) 2004-03-25
AR041219A1 (es) 2005-05-11

Similar Documents

Publication Publication Date Title
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
DOP2002000525A (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion.
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
BR9815785A (pt) Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CR8778A (es) Revestimientos de azucar y metodos para estos
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
CR9580A (es) Inhibidores de la actividad akt
PA8680701A1 (es) Derivados de oxindol
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
ATE217321T1 (de) Aromatische heterocyclische derivate als enzyminhibitoren
CR9475A (es) Derivados de amina substituidos como inhibidores de proteina kinasa
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
BR0316606A (pt) Derivados de aminoindazóis e sua utilização como inibidores de quinases
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
BR9815786A (pt) Quinolonas como inibidores de protease de serina
EA200701782A2 (ru) Производные азаспироалканов в качестве ингибиторов металлопротеаз
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
CR20220199A (es) Inhibidores del factor d del complemento para administración oral

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150129